Our Mission
Establishing a new paradigm for innovative biologics R&D
Symray Biopharma is a high-tech enterprise dedicated to innovative R&D of antibody-based biologics. Guided by clinical value, we leverage an antibody discovery platform covering all species, all epitopes and all functions, a high-throughput, automated antibody characterization platform, and a systematic, tailored drug validation platform, to develop monoclonal antibodies, bispecific antibodies, ADCs and antibody fusion proteins against major diseases. Our highly experienced R&D team, mature technology platforms and extensive off-the-shelf product portfolio enable us to stand out in a highly competitive market.Learn more
Drawing on its three core platforms — antibody discovery, antibody characterization and drug validation — Symray Biopharma connects upstream and downstream players across the drug R&D value chain, providing scientists with a platform for translational innovation and drug developers with high-quality drug candidates. We have established an antibody drug R&D system spanning monoclonal antibodies, bispecific antibodies, ADCs, antibody fusion proteins and CAR-T therapies, with a pipeline covering inflammation, autoimmune diseases, cardiovascular, cerebrovascular and metabolic diseases, ophthalmic diseases and rare diseases.